Haverford Trust Co Purchases New Shares in Stryker Corporation $SYK

Haverford Trust Co acquired a new position in shares of Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 255,083 shares of the medical technology company’s stock, valued at approximately $80,310,000. Haverford Trust Co owned about 0.07% of Stryker as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in SYK. Gables Capital Management Inc. purchased a new position in shares of Stryker during the second quarter worth about $25,000. Kilter Group LLC purchased a new stake in Stryker during the 2nd quarter valued at approximately $25,000. Godfrey Financial Associates Inc. acquired a new stake in Stryker during the 4th quarter worth approximately $26,000. Sankala Group LLC acquired a new stake in Stryker during the 4th quarter worth approximately $26,000. Finally, Compass Financial Management LLC purchased a new position in shares of Stryker in the 2nd quarter valued at approximately $27,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Price Performance

SYK stock opened at $329.86 on Friday. The firm has a 50 day moving average of $326.99 and a 200-day moving average of $332.64. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The company has a market cap of $126.52 billion, a price-to-earnings ratio of 34.18, a PEG ratio of 2.10 and a beta of 0.76. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts expect that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is 36.48%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. Raymond James Financial set a $370.00 price objective on shares of Stryker in a research report on Friday, July 31st. Leerink Partners cut their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Evercore set a $350.00 target price on shares of Stryker in a research note on Monday, July 6th. Finally, Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the completion of the transaction, the director directly owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Debra King sold 826 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 665,370 shares of company stock valued at $216,238,501 over the last quarter. Insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.